Affimed’s $50 Million At-The-Market Offering Program


Davis Polk advised the sales agent, Jefferies LLC, on the deal.

Affimed N.V. executed an SEC-registered at-the-market offering program of up to $50 million gross sales price of its common shares. The common shares are listed on the Nasdaq Global Market under the symbol “AFMD.”

Based in Heidelberg, Germany, Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells.

The Davis Polk capital markets team advising Jefferies included partner Derek Dostal (Picture) and associate Dan Gibbons. Partner Patrick E. Sigmon provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Dan Gibbons – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Patrick Sigmon – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Jefferies;

Author: Ambrogio Visconti